Randomized, open-label comparison of epoetin alfa extended dosing (80 000 U Q2W) vs weekly dosing (40 000 U QW) in patients with chemotherapy-induced anemia.
Curr Med Res Opin
; 22(7): 1403-13, 2006 Jul.
Article
in En
| MEDLINE
| ID: mdl-16834839
OBJECTIVE: This randomized, open-label, multicenter study compared the efficacy and safety of epoetin alfa (EPO) 80 000 U every 2 weeks (Q2W) to the FDA-approved regimen of 40 000 U weekly (QW) in patients with chemotherapy-induced anemia. RESEARCH DESIGN AND METHODS: A total of 310 patients with nonmyeloid malignancy and baseline hemoglobin (Hb)
Subject(s)
Search on Google
Database:
MEDLINE
Main subject:
Erythropoietin
/
Hematinics
/
Anemia
Type of study:
Clinical_trials
/
Guideline
/
Observational_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Curr Med Res Opin
Year:
2006
Type:
Article
Affiliation country:
United States
Search on Google
Database:
MEDLINE
Main subject:
Erythropoietin
/
Hematinics
/
Anemia
Type of study:
Clinical_trials
/
Guideline
/
Observational_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Curr Med Res Opin
Year:
2006
Type:
Article
Affiliation country:
United States